Navigation Links
Another dietary medicine for Alzheimer’s disease: Red cabbage

The findings of a study appearing in the journal LWT - Food Science and Technology say that consumption of red cabbage can reduce the risk of Alzheimer’s disease. //

Ho Jin Heo and Chang Yong Lee from Cornell University led the study and have found that red cabbage extract could significantly reduce build-up of plagues from amyloid deposits that scientists believe attribute to the development of Alzheimer's.

The destructive action of amyloid deposits is increased brain cell damage and death from oxidative stress. The mechanism by which red cabbage helps is through anthocyanins and other cabbage polyphenols proved to be protective against such oxidative stress.

The study tested red and white cabbage and its polyphenol content. Approximately red cabbage contained 190 milligrams (mg) of polyphenols and 23 mg of anthocyanins per 100 grams of fresh weight, compared with 45 mg of polyphenols and 0.01 mg of anthocyanins per 100 grams in white cabbage.

The antioxidant activity of the extracts of red cabbage was about six to eight times higher than that of the extracts from white cabbage. Therefore they have better capability to combat oxidative stress.

As a conclusion researchers said,”Consumption of vegetables such as red cabbages may be beneficial to increase chemopreventive effects in neurodegenerative diseases such as Alzehimer'.
'"/>




Page: 1

Related medicine news :

1. Another ray of hope for Arthritis Sufferers
2. Another injectable contraceptive Pill approved by FDA
3. The Possibility Of Fighting HIV with Another Virus Questioned
4. New Research Has Found Another Use For Botox
5. Yet Another Harmful Consequence Of Smoking
6. Another Treatment Option for Benign Tumors
7. Yet Another Treatment Option For Cancer
8. Another Alternative For Diabetics On Insulin
9. Another Use For Epilepsy Drugs
10. Another Cause of Thyroid Cancer Discovered
11. Yet Another Use For Cell Phone Cameras
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: